STAT OP-ED: Letting academic medical centers make CAR-T drugs would save billions
High prices not only pose a challenge to patient access, but they also raise a fundamental question: Are we creating these therapies the wrong way?
GALLUP: Millions in U.S. Lost Someone Who Couldn’t Afford Treatment
More than 13% of American adults -- or about 34 million people -- report knowing of at least one friend or family member in the past five years who died after not receiving needed medical treatment because they were unable to pay for it.
BLOOMBERG: Sheriffs’ Ads Slammed Drug Imports, and Big Pharma Helped Pay the Tab
Two-year campaign opposing cost-saving plans featured secret payments, a widely criticized consultant's report, and celebrity drug cops.
ICYMI: Big Pharma Sinks to the Bottom of U.S. Industry Rankings
"The pharmaceutical industry is now the most poorly regarded industry in Americans' eyes, ranking last on a list of 25 industries that Gallup tests annually."
Pharma: A Broken Market Begging for Repairs
Government policy keeps U.S. drug prices high, and only government reforms can change that.
10 Drug Corporations Drive One-Third of Taxpayer Spending in Medicare Part D
New data show how negotiating for the 250 most-expensive drugs could save patients, taxpayers billions.
Vertex is pricing life-saving medicines out of reach.
If the children for whom these medicines are created continue to suffer and die, it’s as if the drugs were never made at all.
CHART PACK: New Analysis Shows Lion’s Share Of Part D Spending is For a Small Percentage of Drugs
The analysis, using data from CMS’ Medicare Part D Drug Spending Dashboard, shows that less than 1 percent of drugs accounts for 17 percent of spending and 3.5 percent account for nearly 60 percent of spending.
